Patricia Coyle, MD

home / authors / patricia-coyle-md

Articles

Final Thoughts: Improving QoL in Multiple Sclerosis

Final Thoughts: Improving QoL in Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Optimistic Outlook in Treating Multiple Sclerosis

Optimistic Outlook in Treating Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Patient Support Networks for Multiple Sclerosis

Patient Support Networks for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
OPTIMUM Trial for Multiple Sclerosis

OPTIMUM Trial for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
TRIUMPHANT-MS Trial for Multiple Sclerosis

TRIUMPHANT-MS Trial for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Multiple Sclerosis Fatigue

Multiple Sclerosis Fatigue

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Quality of Life Issues:  Cognitive Changes with MS

Quality of Life Issues:  Cognitive Changes with MS

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Patient’s Journey of Therapies for Multiple Sclerosis

Patient’s Journey of Therapies for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Treatment Options Available for Multiple Sclerosis

Treatment Options Available for Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Managing Psychological Symptoms of Multiple Sclerosis

Managing Psychological Symptoms of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 5th 2021
Psychological Impact of Multiple Sclerosis

Psychological Impact of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
February 3rd 2021
Patient’s Journey: Diagnosis of Multiple Sclerosis

Patient’s Journey: Diagnosis of Multiple Sclerosis

Patricia Coyle, MD;June Halper, MSN, APC-C, MSCN, FAAN;Frederick Foley, PhD
January 25th 2021
The Future of Treating Multiple Sclerosis

The Future of Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Decision-Making Process for Treating Multiple Sclerosis

Decision-Making Process for Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Switching Therapies in Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ozanimod in Multiple Sclerosis

Role of Ozanimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Diroximel Fumarate in Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ocrelizumab in Europe for Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Ocrelizumab for the Treatment of Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Siponimod in Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Treating With Cladribine in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinical Trials for Cladribine in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Glatiramer Acetate in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Interferon in Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
First-Line Therapies for Relapsing Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinically Isolated Syndrome Versus Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
MOG-IgG in Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Differential Diagnosis of Multiple Sclerosis

Differential Diagnosis of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Diagnosis of Multiple Sclerosis: The McDonald Criteria

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Patricia Coyle, MD: Multiple Sclerosis Symptom Management

Patricia Coyle, MD: Multiple Sclerosis Symptom Management

Patricia Coyle, MD
September 18th 2018

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

12>

Latest Updated Articles

Robert A. Hauser, MD, MBA (Credit: USF Health)
Published: October 17th 2024 | Updated: October 21st 2024
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment
Jacob McCauley, PhD (Credit: Miami Miller School of Medicine)
Published: September 18th 2024 | Updated: September 20th 2024
Multi-Ethnic Study Identifies Ancestry-Specific Genetic Variants that Influence Risk of Multiple Sclerosis
Todd Sherer, PhD (Credit: The Michael J. Fox Foundation for Parkinson's Research)
Published: September 9th 2024 | Updated: September 11th 2024
FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Lee Golden, MD (Credit: PTC Therapeutics)
Published: August 24th 2024 | Updated: August 26th 2024
Vatiquinone Pharmacokinetics Influenced by CYP3A4 Inhibitors and Inducers in Phase 1 Study
Renaud Du Pasquier, MD (Credit: University of Lausanne)
Published: August 22nd 2024 | Updated: August 23rd 2024
Novel Cell-Based Assay Enhances Detection of Autoantibodies in Neurological Disorders
Anna Castagna, MD
Published: August 6th 2024 | Updated: August 15th 2024
The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD
© 2024 MJH Life Sciences

All rights reserved.